Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

41.16 +0.26 (+0.62%)
Streaming Delayed Price Updated: 11:23 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gsk Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have  
Via Benzinga
Hope for Endometrial Cancer - GSK Drug Proves Effective in Increasing Survival Rates
GSK plc (NYSE: GSK)  
Via Benzinga
GSK's Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales
GSK (NYSE: GSK) has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer Inc (NYSE: PFE), which previously dominated the COVID-19... 
Via Benzinga
Exposures COVID-19
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Peering Into GSK's Recent Short Interest
Via Benzinga
Price Over Earnings Overview: GSK
Via Benzinga
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
(GSK) - Analyzing GSK's Short Interest
Via Benzinga
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its... 
Via Talk Markets
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less. 
Via InvestorPlace
3 Deeply Undervalued Growth Stocks
As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks. 
Via InvestorPlace
Bank Of America, Mastercard, NRA And Others Are Lobbying For Cannabis Banking Reform — Who Knew?
Several entities have included the Secure and Fair Enforcement Regulation (SAFER) Banking Act on their lobbying disclosures for the third quarter of 2023. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
Price Over Earnings Overview: GSK
Via Benzinga
How Is The Market Feeling About GSK?
Via Benzinga
GSK: Pharma Giant Prioritizing Shareholder Dividends
A good hunting ground for dividend stocks is often companies from which Wall Street wants to see strong performance in the short-term, while its long-term prospects are actually what are most bright. 
Via Talk Markets
Google AI-Powered Chatbot's Ethical Concerns, MGM Hackers Waited For Days Before Issuing Financial Demands, Costco Accused Of Sharing Confidential Health Data With Facebook: Today's Top Stories
Bloomberg Google's AI Dilemma - Bard's Promise Versus Ethical Concerns 
Via Benzinga
Topics Artificial Intelligence Hacking
Exposures Artificial Intelligence Information Security
Little Less Heartburn For GSK: Settles Another California Lawsuit On Zantac
GSK plc (NYSE: GSK) has reached a confidential settlement in the Cantlay/Harper case filed in California state court.  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
China-Based Zhifei Biological Partners With GSK To Expand Shingrix Vaccine Access Across China Via £2.5B Deal
GSK plc (NYSE: GSK) has reached an exclus 
Via Benzinga
Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger, Novo Nordisk's Weight Loss Drugs May Pose Serious Stomach Risks, Netflix's Local Content and Pricing Woes Undermine Growth in India: Today's Top Stories
Bloomberg Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger 
Via Benzinga
GSK Cuts Stake In Consumer Healthcare Business Haleon, Raises Around $1B
GSK Plc (NYSE: GSK) said it raised £885.6 million ( 
Via Benzinga
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
AstraZeneca Plc (NASDAQ: AZN) has  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
7 ‘Smart Money’ Stocks Set to Explode Higher
Invest like the pros by wagering on these top seven smart money stocks to buy at this time, offering tremendous upside ahead. 
Via InvestorPlace
Moderna's Shares Could Take Off if These 2 Things Happen
Moderna stock soared early in the pandemic. 
Via The Motley Fool
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.  More than a million people worldwide succumb to infections caused... 
Via Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Read the latest report on NanoViricides here 
Via Benzinga
Why Are Antifungal Focused Scynexis Stock Plunging Today?
Scynexis Inc (NASDAQ: SCYX) is voluntarily recalling its antifunga 
Via Benzinga
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.